Tanya Dorff, MD, City of Hope Comprehensive Cancer Center

Articles by Tanya Dorff, MD, City of Hope Comprehensive Cancer Center

Emerging Therapies for Advanced Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Radium-223 in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Genetic Testing in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Impact of Clinical Data on the Treatment of mCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

The CARD and PROfound Trials for Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Differences Between AR-Targeted Therapy in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Overall Survival Data Presented at ASCO 2020 for nmCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

FDA Approved Agents for Non-Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Clinical Trials in the Community Setting for Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Data for Metastatic Castration-Sensitive Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Conventional Versus PSMA Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

PSMA-Targeted Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Dr. Dorff on Role of Chemotherapy in mCRPC

ByTanya Dorff, MD, City of Hope Comprehensive Cancer Center

October 6th 2016

Tanya Dorff, MD, assistant professor of Clinical Medicine, Keck Medicine of University of Southern California, discusses the role of chemotherapy in patients with metastatic castration-resistant prostate cancer and pivotal clinical trials that have explored this.

Latest Updated Articles

Dr. Dorff on Role of Chemotherapy in mCRPC
Published: October 6th 2016 | Updated:
FDA Approved Agents for Non-Metastatic CRPC
Published: July 9th 2020 | Updated:
Conventional Versus PSMA Imaging in Prostate Cancer
Published: July 9th 2020 | Updated:
The CARD and PROfound Trials for Metastatic CRPC
Published: July 9th 2020 | Updated:
Emerging Therapies for Advanced Prostate Cancer
Published: July 9th 2020 | Updated:
Data for Metastatic Castration-Sensitive Prostate Cancer
Published: July 9th 2020 | Updated:

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center

Articles by Tanya Dorff, MD, City of Hope Comprehensive Cancer Center

Emerging Therapies for Advanced Prostate Cancer

Radium-223 in Metastatic CRPC

Genetic Testing in Metastatic CRPC

Impact of Clinical Data on the Treatment of mCRPC

The CARD and PROfound Trials for Metastatic CRPC

Differences Between AR-Targeted Therapy in Prostate Cancer

Overall Survival Data Presented at ASCO 2020 for nmCRPC

FDA Approved Agents for Non-Metastatic CRPC

Clinical Trials in the Community Setting for Prostate Cancer

Data for Metastatic Castration-Sensitive Prostate Cancer

Conventional Versus PSMA Imaging in Prostate Cancer

PSMA-Targeted Imaging in Prostate Cancer

Dr. Dorff on Role of Chemotherapy in mCRPC

Latest Updated Articles

Trending on OncLive

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies

TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma